Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of MSD Pharmaceuticals.

Client Virtual Booth
  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
MSD Pharmaceuticals
india-flag Flag
Country
Country
India
Address
Address
Platina, 8th Floor, C.59, G Block, Bandra Kurla Complex, Bandra (East) , Mumbai - 400098,
Telephone
Telephone
+91 22 67898888

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

NOUS-209 (GAd20-209-FSP) is an off-the-shelf cancer immunotherapy for MSI-H tumors. MSI-H tumors are characterized by a defective DNA mismatch repair system, which generates highly immunogenic neoantigens called frame shift peptides that are not present in healthy tissue.


Lead Product(s): GAd20-209-FSP,MVA-209-FSP,Pembrolizumab

Therapeutic Area: Oncology Product Name: NOUS-209

Highest Development Status: Phase IIProduct Type: Vaccine

Recipient: Nouscom AG

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 05, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, PeptiDream will provide peptide candidates identified from PeptiDream’s proprietary Peptide Discovery Platform System (“PDPS”) technology for use as PDCs against targets of interest to MSD.


Lead Product(s): Peptide-drug Conjugate

Therapeutic Area: Technology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Peptide

Recipient: PeptiDream

Deal Size: $2,100.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration December 27, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ATG-037 is an oral, small molecule CD73 inhibitor. CD73 generates adenosine, which leads to immunosuppression in the tumor microenvironment. ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with ICIs and chemotherapy agents.


Lead Product(s): ATG-037,Pembrolizumab

Therapeutic Area: Oncology Product Name: ATG-037

Highest Development Status: Phase IProduct Type: Small molecule

Recipient: Antengene

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration December 26, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency in HRR, such as those with mutations in BRCA1 and/or BRCA2, or those where deficiency is induced by other agents.


Lead Product(s): Olaparib,Abiraterone Acetate

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: AstraZeneca

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 21, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

DR30303 is a humanized anti-Claudin18.2 heavy chain antibody Fc fusion protein (VHH-Fc) generated via Doer Biologics' proprietary SMART-VHHBody platform.


Lead Product(s): DR30303,Pembrolizumab

Therapeutic Area: Oncology Product Name: DR30303

Highest Development Status: PreclinicalProduct Type: Large molecule

Recipient: Zhejiang Doer Biologics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration December 15, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

LYNPARZA (olaparib), is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.


Lead Product(s): Olaparib,Abiraterone Acetate

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: AstraZeneca

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 15, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

PMC-309 is a novel IgG1 anti-VISTA antagonizing antibody that can be used for the treatment of various tumor types. By inhibiting VISTA, it can play a pivotal role in maintaining the immunosuppressive environment around the tumor cells.


Lead Product(s): PMC-309,Pembrolizumab

Therapeutic Area: Oncology Product Name: PMC-309

Highest Development Status: PreclinicalProduct Type: Large molecule

Recipient: PharmAbcine

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration December 12, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. Under the terms of the agreement, Merck will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.


Lead Product(s): VB10.16,Pembrolizumab

Therapeutic Area: Oncology Product Name: VB10.16

Highest Development Status: PreclinicalProduct Type: Vaccine

Recipient: Nykode Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration December 06, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza (olaparib) is first-in-class PARP inhibitor and first targeted treatment to block DNA damage response in cells/tumours harboring deficiency in HRR.


Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: AstraZeneca

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 14, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The approval by CNMPA was based on HRD-positive subgroup exploratory analysis of PAOLA-1 Phase III trial which showed Lynparza (olaparib) plus bevacizumab demonstrated a substantial PFS improvement versus bevacizumab for patients with HRD-positive advanced ovarian cancer.


Lead Product(s): Olaparib,Bevacizumab

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: AstraZeneca

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 22, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY